Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

27.09.2016: WILEX AG: Subsidiary Heidelberg Pharma contracts Suisse CDMO Celonic for antibody cell line development and antibody production: WILEX AG today announced that its subsidiary Heidelberg Pharma, has signed an agreement with Celonic AG, Basel, Switzerland, a specialist in the development and manufacturing of biologics (CDMO). ...More




Seite gelesen: 569492 | Heute: 221